Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

PubWeight™: 4.82‹?› | Rank: Top 1%

🔗 View Article (PMC 3278051)

Published in Chest on February 01, 2012

Authors

Walter Ageno1, Alexander S Gallus, Ann Wittkowsky, Mark Crowther, Elaine M Hylek, Gualtiero Palareti, American College of Chest Physicians

Author Affiliations

1: University of Insubria, Varese, Italy. walter.ageno@uninsubria.it

Associated clinical trials:

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome | NCT00809965

Articles citing this

(truncated to the top 100)

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace (2015) 2.67

Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol (2014) 2.17

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood (2014) 1.61

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.59

Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Thromb Res (2015) 1.43

Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study. PLoS One (2015) 1.40

Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40

Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ (2012) 1.28

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26

Laboratory assessment of rivaroxaban: a review. Thromb J (2013) 1.16

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15

Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Can Fam Physician (2014) 1.07

Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J (2014) 1.05

Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol (2013) 1.05

New anticoagulants: A concise review. J Trauma Acute Care Surg (2012) 1.04

2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg (2014) 0.99

Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res (2013) 0.98

Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98

The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J (2013) 0.95

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol (2014) 0.95

Dabigatran and kidney disease: a bad combination. Clin J Am Soc Nephrol (2013) 0.95

Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93

Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series. Drugs R D (2013) 0.92

New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther (2014) 0.92

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol (2015) 0.92

New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J (2013) 0.88

Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep (2016) 0.87

New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87

The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86

Anticoagulation drug therapy: a review. West J Emerg Med (2015) 0.86

Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. Blood Transfus (2015) 0.85

Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. J Am Heart Assoc (2015) 0.85

Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83

A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics. CPT Pharmacometrics Syst Pharmacol (2015) 0.83

Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series. J Med Toxicol (2014) 0.83

Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy. P T (2013) 0.83

Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era. Vasc Health Risk Manag (2016) 0.83

New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83

Management of bleeding in patients treated with direct oral anticoagulants. Crit Care (2016) 0.82

Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82

Warfarin pharmacogenomics in children. Pediatr Blood Cancer (2013) 0.82

Budget impact analysis of warfarin reversal therapies among hip fracture patients in Finland. Drugs R D (2015) 0.82

Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. Ochsner J (2013) 0.82

Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. BMC Med Genomics (2014) 0.82

Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis (2016) 0.81

A new paradigm shift in antithrombotic therapy. Front Pharmacol (2013) 0.81

Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion (2015) 0.81

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor. Front Physiol (2014) 0.81

Warfarin pharmacogenetics: challenges and opportunities for clinical translation. Front Pharmacol (2012) 0.81

Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.81

Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J (2016) 0.81

Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis (2014) 0.80

Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.80

Implanted cell-dense prevascularized tissues develop functional vasculature that supports reoxygenation after thrombosis. Tissue Eng Part A (2014) 0.80

Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. PLoS One (2014) 0.80

Patients' perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy. Ther Adv Drug Saf (2014) 0.80

Expanding use of new oral anticoagulants. F1000Prime Rep (2014) 0.80

Practical management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskelet Surg (2013) 0.80

Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials. Acad Emerg Med (2016) 0.80

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One (2015) 0.79

Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE. Nat Rev Cardiol (2012) 0.79

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag (2014) 0.79

Score for atrial fibrillation detection in acute stroke and transient ischemic attack patients in a Brazilian population: the acute stroke atrial fibrillation scoring system. Clinics (Sao Paulo) (2014) 0.79

A novel algorithm for analyzing drug-drug interactions from MEDLINE literature. Sci Rep (2015) 0.79

The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy. Hematol Oncol Clin North Am (2016) 0.79

Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study. Thrombosis (2015) 0.78

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc (2015) 0.78

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. Br J Clin Pharmacol (2015) 0.78

Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature. BMC Pharmacol Toxicol (2013) 0.78

Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag (2015) 0.78

Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.78

Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.78

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants (DOACs): A Systematic Review. Chest (2016) 0.78

Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. World J Gastrointest Oncol (2016) 0.77

Steps to consider in the approach and management of critically ill patient with spontaneous intracerebral hemorrhage. World J Crit Care Med (2015) 0.77

Comparison of international normalized ratio measurement between CoaguChek XS Plus and STA-R coagulation analyzers. Biomed Res Int (2012) 0.77

The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. Br J Clin Pharmacol (2016) 0.77

The use of novel oral anticoagulants: the debate continues! Blood Transfus (2015) 0.77

Patients' and physicians' satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic. BMC Res Notes (2015) 0.77

Long-term prognosis and related factors towards patients with acute pulmonary thromboembolism. Int J Clin Exp Med (2015) 0.77

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag (2016) 0.77

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thromb J (2014) 0.77

The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One (2015) 0.76

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. Curr Orthop Pract (2015) 0.76

Rivaroxaban delivery and reversal at a venous flow rate. Arterioscler Thromb Vasc Biol (2012) 0.76

An acenocoumarol dose algorithm based on a South-Eastern European population. Eur J Clin Pharmacol (2013) 0.76

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects. Clin Pharmacol Drug Dev (2016) 0.76

Factor XIa inhibitors: A review of the patent literature. Expert Opin Ther Pat (2016) 0.76

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther (2015) 0.76

Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding. PLoS One (2013) 0.76

Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. J Thromb Haemost (2015) 0.75

Factors influencing warfarin response in hospitalized patients. Saudi Pharm J (2015) 0.75

Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. Springerplus (2016) 0.75

Warfarin-induced skin necrosis. Hosp Pharm (2014) 0.75

Articles cited by this

(truncated to the top 100)

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63

Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet (1998) 10.42

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet (1989) 10.18

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med (1992) 9.71

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med (2003) 8.33

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med (1999) 7.74

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet (1996) 6.58

Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol (1991) 6.55

Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA (1998) 6.34

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95

Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26

Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16

Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet (2006) 5.11

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91

Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med (2008) 4.83

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70

Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54

Identification of the gene for vitamin K epoxide reductase. Nature (2004) 4.52

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med (1993) 4.03

Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med (1998) 3.91

Computer control of anticoagulant dose for therapeutic management. BMJ (1989) 3.87

Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev (1989) 3.87

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med (1996) 3.86

The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med (1996) 3.79

Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ (2003) 3.73

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet (2008) 3.73

A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60

Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med (1998) 3.44

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest (1975) 3.40

Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med (1994) 3.33

Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A (1974) 3.24

Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med (1990) 3.19

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol (1998) 3.17

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol (2007) 3.09

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet (1996) 3.03

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2010) 3.03

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet (2008) 3.00

The hemostatic defect produced by carbenicillin. N Engl J Med (1974) 2.99

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation (2008) 2.98

Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med (1998) 2.98

Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med (2002) 2.85

Effect of automation on prothrombin time test in NEQAS surveys. J Clin Pathol (1989) 2.84

Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med (2004) 2.83

Failure of the International Normalized Ratio to generate consistent results within a local medical community. Am J Clin Pathol (1993) 2.81

Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest (2006) 2.79

New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost (2010) 2.73

Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol (1993) 2.73

The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol (2003) 2.71

Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet (2010) 2.65

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63

Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med (2005) 2.63

The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem (1974) 2.59

Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc (1995) 2.55

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.54

Computer assisted management of warfarin treatment. Br Med J (Clin Res Ed) (1984) 2.54

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53

Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol (2005) 2.53

Drug interactions with tobacco smoking. An update. Clin Pharmacokinet (1999) 2.52

Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med (1995) 2.51

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50

Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med (1980) 2.50

Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med (1996) 2.50

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos (2007) 2.47

Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40

Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation. J Clin Pathol (1991) 2.34

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30

Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood (2006) 2.27

Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol (2008) 2.27

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25

Articles by these authors

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 18.90

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95

ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12

Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med (2011) 6.56

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.99

Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88

Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.29

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

The "gender gap" in authorship of academic medical literature--a 35-year perspective. N Engl J Med (2006) 5.23

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.02

Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med (2008) 4.83

Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77

Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.50

Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.49

Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.30

Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.29

Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest (2005) 4.29

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.87

Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86

Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.81

Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest (2001) 3.77

The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ (2006) 3.58

Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.56

Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest (2003) 3.55

The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47

Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 3.46

Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36

Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest (2007) 3.36

Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.31

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med (2012) 3.16

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.14

ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr (2011) 3.13

Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation (2009) 3.10

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.08

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06

N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90

An Official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units. Am J Respir Crit Care Med (2015) 2.86

Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.83

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.83

Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost (2011) 2.75

Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.74

Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.72

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68

Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation (2011) 2.60

Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.60

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.55

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.54

Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med (2013) 2.52

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50

Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Antiphospholipid syndrome. Lancet (2010) 2.47

Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.47

Grades of recommendation for antithrombotic agents. Chest (2001) 2.44

Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26

Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest (2013) 2.24

Practice parameters for the use of portable monitoring devices in the investigation of suspected obstructive sleep apnea in adults. Sleep (2003) 2.21

Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16

Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16

The solitary pulmonary nodule. Chest (2003) 2.09

A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol (2012) 2.07

Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.06

Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. Intern Emerg Med (2009) 2.03

Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest (2007) 2.02

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.00

Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest (2007) 1.99

Sleep apnea and commercial motor vehicle operators: Statement from the joint task force of the American College of Chest Physicians, the American College of Occupational and Environmental Medicine, and the National Sleep Foundation. Chest (2006) 1.99

Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med (2001) 1.95

Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.94

Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87

Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.85

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85